Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...
Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...
After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post Could CSL shares outperform the ASX 200 in 2026? appeared first on The Motley ...
Shares of the Australia-based CSL Ltd. (AU:CSL) fell by over 4% as of writing despite the company achieving higher profit in FY24. The company reported an NPAT (net profit after tax) attributable to ...
Should you be buying the dip? Let's find out. The post Why did CSL shares crash 39% in 2025? appeared first on The Motley Fool Australia.
CSLLY's FY 2024 results were good thanks to the outperformance of the Behring segment; the company's net profit in constant currency terms grew +15% YoY to $2.91 billion, which was in line with ...
Good morning, everyone, and welcome to CSL's Financial Year 2024 Results Presentation. I'm Joy Linton, CSL's Chief Financial Officer. And before we begin the formalities today, I would like to say a ...
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...
Wilsons analyst Shane Storey maintained a Buy rating on CSL (CMXHF – Research Report) on January 22 and set a price target of A$352.64. The company’s shares closed yesterday at $188.75. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback